Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever.


Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
24 06 2021
Historique:
received: 25 11 2020
revised: 19 03 2021
accepted: 29 04 2021
pubmed: 3 6 2021
medline: 6 1 2022
entrez: 2 6 2021
Statut: ppublish

Résumé

Crimean-Congo hemorrhagic fever virus (CCHFV) is a World Health Organization priority pathogen. CCHFV infections cause a highly lethal hemorrhagic fever for which specific treatments and vaccines are urgently needed. Here, we characterize the human immune response to natural CCHFV infection to identify potent neutralizing monoclonal antibodies (nAbs) targeting the viral glycoprotein. Competition experiments showed that these nAbs bind six distinct antigenic sites in the Gc subunit. These sites were further delineated through mutagenesis and mapped onto a prefusion model of Gc. Pairwise screening identified combinations of non-competing nAbs that afford synergistic neutralization. Further enhancements in neutralization breadth and potency were attained by physically linking variable domains of synergistic nAb pairs through bispecific antibody (bsAb) engineering. Although multiple nAbs protected mice from lethal CCHFV challenge in pre- or post-exposure prophylactic settings, only a single bsAb, DVD-121-801, afforded therapeutic protection. DVD-121-801 is a promising candidate suitable for clinical development as a CCHFV therapeutic.

Identifiants

pubmed: 34077751
pii: S0092-8674(21)00584-5
doi: 10.1016/j.cell.2021.05.001
pmc: PMC8559771
mid: NIHMS1702235
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Neutralizing 0
Antigens, Viral 0
Epitopes 0
Immunoglobulin G 0
Recombinant Proteins 0
Viral Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3486-3501.e21

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI132246
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI070117
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142777
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests K.C. is a scientific advisory board member of Integrum Scientific and Biovaxys Technology Corporation. K.C., J.S.M., and J.R.L. are scientific advisory board members of the Pandemic Security Initiative of Celdara Medical. N.T.P. and L.M.W. are employees and shareholders of Adimab. D.P.M. is a shareholder of Adimab. Z.A.B., D.M.A., C.L.M., and L.Z. are shareholders and employees of Mapp Biopharmaceutical. Mapp Biopharmaceutical has filed a patent application related to this work.

Références

Cell. 2002 Mar 8;108(5):717-25
pubmed: 11893341
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6795-9
pubmed: 23569243
J Gen Virol. 2010 Jun;91(Pt 6):1473-7
pubmed: 20164263
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6675-6685
pubmed: 32152119
Science. 2016 Oct 21;354(6310):350-354
pubmed: 27608667
J Virol. 2005 May;79(10):6152-61
pubmed: 15858000
mBio. 2015 Nov 03;6(6):e01559-15
pubmed: 26530385
Nat Biotechnol. 2007 Nov;25(11):1290-7
pubmed: 17934452
Toxins (Basel). 2015 May 29;7(6):1854-81
pubmed: 26035486
Protein Eng Des Sel. 2013 Oct;26(10):663-70
pubmed: 24046438
EMBO J. 2009 Oct 21;28(20):3269-76
pubmed: 19713934
Rev Infect Dis. 1989 May-Jun;11 Suppl 4:S801-6
pubmed: 2501854
Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8
pubmed: 26216974
Emerg Infect Dis. 2015 Jan;21(1):23-31
pubmed: 25529825
PLoS Negl Trop Dis. 2015 Dec 01;9(12):e0004259
pubmed: 26625182
Viruses. 2020 Feb 27;12(3):
pubmed: 32120864
Nature. 2015 Jun 25;522(7557):487-91
pubmed: 25855300
Cell Rep. 2018 Nov 6;25(6):1385-1394.e7
pubmed: 30403995
Nat Microbiol. 2018 May;3(5):556-562
pubmed: 29632370
Nature. 2014 Mar 13;507(7491):201-6
pubmed: 24499818
Cell. 2019 May 30;177(6):1566-1582.e17
pubmed: 31104840
J Virol. 1998 Apr;72(4):3235-40
pubmed: 9525650
Cell Host Microbe. 2019 Jan 9;25(1):39-48.e5
pubmed: 30629917
Cell Host Microbe. 2019 Jan 9;25(1):49-58.e5
pubmed: 30629918
Sci Immunol. 2017 Aug 18;2(14):
pubmed: 28821561
Immunity. 2019 Aug 20;51(2):398-410.e5
pubmed: 31350180
Clin Infect Dis. 2004 Jun 15;38(12):1731-5
pubmed: 15227619
Science. 2010 May 7;328(5979):745-8
pubmed: 20448183
Virol J. 2012 Jun 19;9:122
pubmed: 22713837
Antiviral Res. 2017 Oct;146:112-120
pubmed: 28842265
Nature. 2010 Dec 2;468(7324):709-12
pubmed: 21124458
Clin Microbiol Infect. 2006 Jun;12(6):551-4
pubmed: 16700704
Trans R Soc Trop Med Hyg. 2015 Aug;109(8):503-13
pubmed: 26142451
PLoS Med. 2006 Jul;3(7):e237
pubmed: 16796401
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Methods Mol Biol. 2006;313:107-20
pubmed: 16118429
Science. 2016 Mar 4;351(6277):1078-83
pubmed: 26912366
Immunity. 2018 Feb 20;48(2):339-349.e5
pubmed: 29396163
Vector Borne Zoonotic Dis. 2015 Dec;15(12):759-64
pubmed: 26684523
Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4055-4059
pubmed: 28396438
Viruses. 2016 Apr 21;8(4):106
pubmed: 27110812
Nat Microbiol. 2019 Jul;4(7):1231-1241
pubmed: 30936489
EMBO Mol Med. 2016 Mar 31;8(4):407-21
pubmed: 26992832
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
PLoS Pathog. 2019 Nov 7;15(11):e1008061
pubmed: 31697791
PLoS Pathog. 2016 Oct 26;12(10):e1005813
pubmed: 27783711
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
J Med Entomol. 1979 May 22;15(4):307-417
pubmed: 113533
Immunity. 2020 Feb 18;52(2):388-403.e12
pubmed: 32023489
PLoS One. 2016 Nov 23;11(11):e0166744
pubmed: 27880794
Sci Adv. 2019 Jul 10;5(7):eaaw9535
pubmed: 31309159
mBio. 2020 Mar 24;11(2):
pubmed: 32209676
Cell Host Microbe. 2010 Sep 16;8(3):271-83
pubmed: 20833378
Nat Struct Mol Biol. 2008 Mar;15(3):312-7
pubmed: 18264114
Nat Commun. 2017 May 23;8:15411
pubmed: 28534525
Cell. 2020 Oct 15;183(2):442-456.e16
pubmed: 32937107
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
Sci Immunol. 2016 Dec 16;1(6):
pubmed: 28111638
PLoS Negl Trop Dis. 2019 Apr 25;13(4):e0007100
pubmed: 31022170
Nat Med. 2017 Oct;23(10):1146-1149
pubmed: 28869611
Antiviral Res. 2013 Oct;100(1):159-89
pubmed: 23906741
Cochrane Database Syst Rev. 2018 Jun 05;6:CD012713
pubmed: 29869797
J Mol Biol. 2013 Jan 23;425(2):444-56
pubmed: 23159556
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
PLoS Pathog. 2012;8(10):e1002930
pubmed: 23055922
Science. 2019 Dec 6;366(6470):
pubmed: 31672916
Virology. 1980 Jul 15;104(1):139-48
pubmed: 6156537
Pediatrics. 1998 Sep;102(3 Pt 1):531-7
pubmed: 9738173
MAbs. 2013 May-Jun;5(3):358-63
pubmed: 23549062
J Gen Virol. 2007 Apr;88(Pt 4):1169-1174
pubmed: 17374760
Science. 2016 Aug 19;353(6301):823-6
pubmed: 27417494
Antiviral Res. 2018 Feb;150:137-147
pubmed: 29199036
Science. 2020 May 15;368(6492):
pubmed: 32409444
Cell. 2001 Apr 6;105(1):137-48
pubmed: 11301009
Emerg Infect Dis. 2018 Sep;24(9):
pubmed: 30124424
Mol Phylogenet Evol. 2010 Jun;55(3):1103-10
pubmed: 20074652
PLoS Negl Trop Dis. 2020 Aug 13;14(8):e0008637
pubmed: 32790668
Nature. 2013 Jan 24;493(7433):552-6
pubmed: 23292515
J Virol. 2020 Mar 31;94(8):
pubmed: 31996434
J Infect Dis. 2013 Jun 15;207(12):1909-21
pubmed: 23417661
J Virol. 2001 Dec;75(24):12198-208
pubmed: 11711611
J Exp Med. 2016 Apr 4;213(4):469-81
pubmed: 27022144
J Virol. 2010 Nov;84(21):11089-100
pubmed: 20739514
Nat Commun. 2019 Feb 20;10(1):879
pubmed: 30787296
Nature. 2012 Dec 6;492(7427):118-22
pubmed: 23103874
Curr Opin Virol. 2019 Feb;34:70-78
pubmed: 30660091

Auteurs

J Maximilian Fels (JM)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Daniel P Maurer (DP)

Adimab, LLC, Lebanon, NH 03766, USA.

Andrew S Herbert (AS)

U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA; The Geneva Foundation, Tacoma, WA 98402, USA.

Ariel S Wirchnianski (AS)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Deparment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Olivia Vergnolle (O)

Deparment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Robert W Cross (RW)

Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77550, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA.

Dafna M Abelson (DM)

Mapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.

Crystal L Moyer (CL)

Mapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.

Akaash K Mishra (AK)

Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.

Jennifer T Aguilan (JT)

Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Ana I Kuehne (AI)

U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.

Noel T Pauli (NT)

Adimab, LLC, Lebanon, NH 03766, USA.

Russell R Bakken (RR)

U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.

Elisabeth K Nyakatura (EK)

Deparment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Jan Hellert (J)

Structural Virology Unit, Department of Virology, CNRS UMR 3569, Institut Pasteur, Paris 75724, France.

Gregory Quevedo (G)

Deparment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Leslie Lobel (L)

Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.

Stephen Balinandi (S)

Uganda Virus Research Institute, Entebbe, Uganda.

Julius J Lutwama (JJ)

Uganda Virus Research Institute, Entebbe, Uganda.

Larry Zeitlin (L)

Mapp Biopharmaceutical, Inc., San Diego, CA 92121, USA.

Thomas W Geisbert (TW)

Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77550, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA.

Felix A Rey (FA)

Structural Virology Unit, Department of Virology, CNRS UMR 3569, Institut Pasteur, Paris 75724, France.

Simone Sidoli (S)

Deparment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Jason S McLellan (JS)

Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.

Jonathan R Lai (JR)

Deparment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Zachary A Bornholdt (ZA)

Mapp Biopharmaceutical, Inc., San Diego, CA 92121, USA. Electronic address: zachary.bornholdt@mappbio.com.

John M Dye (JM)

U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA. Electronic address: john.m.dye1.civ@mail.mil.

Laura M Walker (LM)

Adimab, LLC, Lebanon, NH 03766, USA; Adagio Therapeutics, Inc., Waltham, MA 02451, USA. Electronic address: laura.walker@adimab.com.

Kartik Chandran (K)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: kartik.chandran@einsteinmed.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH